Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tvax-028

Phase 1

GGrand Theravac Life Sciences (Nanjing) Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

HBV InfectionNot yet recruiting

HBV InfectionPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

HBV Infection

NCT07673068

Clinical

Trials by Indication[1]

HBV Infection1 trial

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 Injection in Patients With Chronic Hepatitis B

Not yet recruiting·GGrand Theravac Life Sciences (Nanjing) Co., Ltd.·Phase 1·NCT07673068·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tvax-028. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tvax-028. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Grand Theravac Life Sciences (Nanjing) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: GGrand Theravac Life Sciences (Nanjing) Co., Ltd.

Related News